Influence of molecular parameters and increasing magnetic field strength on relaxivity of gadolinium- and manganese-based T1 contrast agents

Contrast Media and Molecular Imaging

Volumn 4, Issue 2, 2009, Pages 89-100

  Caravan, Peter ^a   Farrar, Christian T ^a   Frullano, Luca ^a   Uppal, Ritika ^a  

^a MASSACHUSETTS GENERAL HOSPITAL   (United States)

Author keywords

Gadolinium; High field; Magnetic resonance imaging; Manganese; Relaxometry

Indexed keywords

EP 2104R; GADOFOSVESET; GADOLINIUM CHELATE; GADOLINIUM PENTETATE; GADOLINIUM PENTETATE ALBUMIN; GADOTERIC ACID; MANGANESE CHLORIDE; MANGANESE DERIVATIVE; MNL 1; UNCLASSIFIED DRUG;

ARTICLE; CONTROLLED STUDY; HYDRATION; MAGNETIC FIELD; PRIORITY JOURNAL; SIMULATION; THEORETICAL STUDY;

CONTRAST MEDIA; GADOLINIUM; MAGNETIC RESONANCE IMAGING; MANGANESE;

EID: 65649118200     PISSN: 15554309     EISSN: 15554317     Source Type: Journal    
DOI: 10.1002/cmmi.267     Document Type: Article

References (65)

1. Vaughan T, DelaBarre L, Snyder C, Tian J, Akgun C, Shrivastava D, Liu W, Olson C, Adriany G, Strupp J, Andersen P, Gopinath A, van de Moortele PF, Garwood M, Ugurbil K. 9.4T human MRI: preliminary results. Magn. Reson. Med. 2006; 56: 1274-1282.
2. Caravan P, Ellison JJ, McMurry TJ, Lauffer RB. Gadolinium(III) Chelates as MRI contrast agents: structure, dynamics, and applications. Chem. Rev. 1999; 99: 2293-2352.
3. Caravan P, Lauffer RB. Contrast agents: basic principles. In Clinical Magnetic Resonance Imaging, 3rd edn, Vol. 1, Edelman RR, Hesselink JR, Zlatkin MB, Crues JV (eds). Saunders: Philadelphia, PA, 2005; 357-375.
4. 2O relaxation in vivo. Magn. Reson. Med. 2007; 57: 308-318.
5. Rohrer M, Bauer H, Mintorovitch J, Requardt M, Weinmann HJ. Comparison of magnetic properties of MRI contrast media solutions at different magnetic field strengths. Invest. Radiol. 2005; 40: 715-724.
6. Caravan P. Strategies for increasing the sensitivity of gadolinium based MRI contrast agents. Chem. Soc. Rev. 2006; 35: 512-523.
7. Mulder WJ, Strijkers GJ, Briley-Saboe KC, Frias JC, Aguinaldo JG, Vucic E, Amirbekian V, Tang C, Chin PT, Nicolay K, Fayad ZA. Molecular imaging of macrophages in atherosclerotic plaques using bimodal PEG-micelles. Magn. Reson. Med. 2007; 58: 1164-1170.
8. Sosnovik DE, Schellenberger EA, Nahrendorf M, Novikov MS, Matsui T, Dai G, Reynolds F, Grazette L, Rosenzweig A, Weissleder R, Josephson L. Magnetic resonance imaging of cardiomyocyte apoptosis with a novel magneto-optical nanoparticle. Magn. Reson. Med. 2005; 54: 718-724.
9. Schmieder AH, Winter PM, Caruthers SD, Harris TD, Williams TA, Allen JS, Lacy EK, Zhang H, Scott MJ, Hu G, Robertson JD, Wickline SA, Lanza GM. Molecular MR imaging of melanoma angiogenesis with alphanubeta3-targeted paramagnetic nanoparticles. Magn. Reson. Med. 2005; 53: 621-627.
10. Thomsen HS, Marckmann P. Extracellular Gd-CA: differences in prevalence of NSF. Eur. J. Radiol. 2008; 66: 180-183.
11. Marckmann P. An epidemic outbreak of nephrogenic systemic fibrosis in a Danish hospital. Eur. J. Radiol. 2008; 66: 187-190.
12. Grobner T, Prischl FC. Gadolinium and nephrogenic systemic fibrosis. Kidney Int. 2007; 72: 260-264.
13. Cowper SE. Nephrogenic systemic fibrosis: a review and exploration of the role of gadolinium. Adv. Dermatol. 2007; 23: 131-154.
14. de Sousa PL, Livramento JB, Helm L, Merbach AE, Meme W, Doan BT, Beloeil JC, Prata MI, Santos AC, Geraldes CF, Toth E. In vivo MRI assessment of a novel GdIII-based contrast agent designed for high magnetic field applications. Contrast Media Mol. Imag. 2008; 3: 78-85.
15. Livramento JB, Helm L, Sour A, O'Neil C, Merbach AE, Toth E. A benzene-core trinuclear GdIII complex: towards the optimization of relaxivity for MRI contrast agent applications at high magnetic field. Dalton Trans. 2008: 1195-1202.
16. Livramento JB, Sour A, Borel A, Merbach AE, Toth E. A starburst-shaped heterometallic compound incorporating six densely packed gd(3+) ions. Chem. Eur. J. 2006; 12: 989-1003.
17. Livramento JB, Toth E, Sour A, Borel A, Merbach AE, Ruloff R. High relaxivity confined to a small molecular space: a metallostar-based, potential MRI contrast agent. Angew. Chem. Int. Edn Engl. 2005; 44: 1480-1484.
18. Livramento JB, Weidensteiner C, Prata MI, Allegrini PR, Geraldes CF, Helm L, Kneuer R, Merbach AE, Santos AC, Schmidt P, Toth E. First in vivo MRI assessment of a self-assembled metallostar compound endowed with a remarkable high field relaxivity. Contrast Media Mol. Imag. 2006; 1: 30-39.
19. Hanaoka K, Lubag AJ, Castillo-Muzquiz A, Kodadek T, Sherry AD. The detection limit of a Gd(3+)-based T(1) agent is substantially reduced when targeted to a protein microdomain. Magn. Reson. Imag. 2008; 26: 608-617.
20. McConnell HM. Reaction rates by nuclear magnetic resonance. J. Chem. Phys. 1958; 28: 430-431.
21. 17 in aqueous solutions of paramagnetic cations and the lifetime of water molecules in the first coordination sphere. J. Chem. Phys. 1962; 37: 307-320.
22. Solomon I. Relaxation processes in a system of two spins. Phys. Rev. 1955; 99: 559-565.
23. Bloembergen N, Morgan LO. Proton relaxation times in paramagnetic solutions. Effects of electron spin relaxation. J. Chem. Phys. 1961; 34: 842-850.
24. Gueron M. Nuclear Relaxation in macromolecules by paramagnetic ions: a novel mechanism. J. Magn. Reson. 1975; 19: 58-66.
25. 3+ contrast agents. J. Phys. Chem. A 2001; 105: 9323-9327.
26. 3+ chelates: LODEPR measurements and models for electron spin relaxation. J. Phys. Chem. A 2002; 106: 6229-6231.
27. Belorizky E, Fries PH. Simple analytical approximation of the longitudinal electronic relaxation rate of Gd(III) complexes in solutions. Phys. Chem. Chem. Phys. 2004; 6: 2341-2351.
28. Caravan P, Parigi G, Chasse JM, Cloutier NJ, Ellison JJ, Lauffer RB, Luchinat C, McDermid SA, Spiller M, McMurry TJ. Albumin binding, relaxivity, and water exchange kinetics of the diastereoisomers of MS-325, a gadolinium(III)-based magnetic resonance angiography contrast agent. Inorg. Chem. 2007; 46: 6632-6639.
29. Freed JH. Dynamic effects of pair correlation functions on spin relaxation by translational diffusion in liquids. II. Finite jumps and independent T1 processes. J. Chem. Phys. 1978; 68: 4034-4037.
30. Hwang L-P, Freed JH. Dynamic effects of pair correlation functions on spin relaxation by translational diffusion in liquids. J. Chem. Phys. 1975; 63: 4017-4025.
31. Borel A, Helm L, Merbach AE. Molecular dynamics simulations of MRI-relevant GdIII chelates: direct access to outer-sphere relaxivity. Chem. Eur. J. 2001; 7: 600-610.
32. Zhang Z, Greenfield MT, Spiller M, McMurry TJ, Lauffer RB, Caravan P. Multilocus binding increases the relaxivity of protein-bound MRI contrast agents. Angew. Chem. Int. Edn Engl. 2005; 44: 6766-6769.
33. Nicolle GM, Toth E, Schmitt-Willich H, Raduchel B, Merbach AE. The impact of rigidity and water exchange on the relaxivity of a dendritic MRI contrast agent. Chem. Eur. J. 2002; 8: 1040-1048.
34. Wiener EC, Brechbiel MW, Brothers H, Magin RL, Gansow OA, Tomalia DA, Lauterbur PC. Dendrimer-based metal chelates: a new class of magnetic resonance imaging contrast agents. Magn. Reson. Med. 1994; 31: 1-8.
35. Lipari G, Szabo A. Model-free approach to the interpretation of nuclear magnetic resonance relaxation in macromolecules. 1. Theory and range of validity. J. Am. Chem. Soc. 1982; 104: 4546-4559.
36. n polymer. J. Biol. Inorg. Chem. 2001; 6: 247-255.
37. Laus S, Sour A, Ruloff R, Toth E, Merbach AE. Rotational dynamics account for pH-dependent relaxivities of PAMAM dendrimeric, Gd-based potential MRI contrast agents. Chem. Eur. J. 2005; 11: 3064-3076.
38. Troughton JS, Greenfield MT, Greenwood JM, Dumas S, Wiethoff AJ, Wang J, Spiller M, McMurry TJ, Caravan P. Synthesis and evaluation of a high relaxivity manganese(II)-based MRI contrast agent. Inorg. Chem. 2004; 43: 6313-6323.
39. Caravan P, Astashkin AV, Raitsimring AM. The gadolinium(III)-water hydrogen distance in MRI contrast agents. Inorg. Chem. 2003; 42: 3972-3974.
40. 3+ complexes in orientationally disordered systems. J. Phys. Chem. A 2004; 108: 1900-2001.
41. 7O pulsed electron nuclear double resonance study of gadolinium complexes with water. J. Phys. Chem. A 2004; 108: 7318-7323.
42. 3+ complexes in glassy solutions. Appl. Magn. Reson. 2005; 28: 281-295.
43. Zech S, Sun W-C, Jacques V, Caravan P, Astashkin AV, Raitsimring AM. Probing the water coordination of protein-targeted MRI contrast agents by pulsed ENDOR spectroscopy. Chem. Phys. Chem. 2005; 6: 2570-2577.
44. 2)Y(-2) ion. Inorg. Chem. 1964; 3: 27-33.
45. Caravan P, Cloutier NJ, Greenfield MT, McDermid SA, Dunham SU, Bulte JW, Amedio JC Jr, Looby RJ, Supkowski RM, Horrocks WD Jr, McMurry TJ, Lauffer RB. The interaction of MS-325 with human serum albumin and its effect on proton relaxation rates. J. Am. Chem. Soc. 2002; 124: 3152-3162.
46. Aime S, Botta M, Terreno E, Anelli PL, Uggeri F. Gd(DOT-P) 5-outer-sphere relaxation enhancement promoted by nitrogen bases. Magn. Reson. Med. 1993; 30: 583-591.
47. Caravan P, Greenfield MT, Li X, Sherry AD. The Gd(3+) complex of a fatty acid analogue of DOTP binds to multiple albumin sites with variable water relaxivities. Inorg. Chem. 2001; 40: 6580-6587.
48. Lebduskova P, Hermann P, Helm L, Toth E, Kotek J, Binnemans K, Rudovsky J, Lukes I, Merbach AE. Gadolinium(III) complexes of mono- and diethyl esters of monophosphonic acid analogue of DOTA as potential MRI contrast agents: solution structures and relaxometric studies. Dalton Trans. 2007: 493-501.
49. Kotek J, Lebduskova P, Hermann P, Vander Elst L, Muller RN, Geraldes CF, Maschmeyer T, Lukes I, Peters JA. Lanthanide(III) complexes of novel mixed carboxylic-phosphorus acid derivatives of diethylenetriamine: a step towards more efficient MRI contrast agents. Chem. Eur. J. 2003; 9: 5899-5915.
50. Aime S, Botta M, Frullano L, Geninatti Crich S, Giovenzana G, Pagliarin R, Palmisano G, Sirtori FR, Sisti M. [GdPCP2A (H(2)O)(2)](-): a paramagnetic contrast agent designed for improved applications in magnetic resonance imaging. J. Med. Chem. 2000; 43: 4017-4024.
51. Toth E, Burai L, Brucher E, Merbach AE. Tuning water-exchange rates on (carboxymethyl(iminobis(ethylenenitriolo)tetraacetate (dtpa)-type gadolinium(III) complexes. Dalton Trans. 1997; 1587-1594.
52. Lauffer RB. Targeted relaxation enhancement agents for MRI. Magn. Reson. Med. 1991; 22: 339.
53. Boxerman JL, Hamberg LM, Rosen BR, Weisskoff RM. MR contrast due to intravascular magnetic susceptibility perturbations. Magn. Reson. Med. 1995; 34: 555-566.
54. Fulton DA, Elemento EM, Aime S, Chaabane L, Botta M, Parker D. Glycoconjugates of gadolinium complexes for MRI applications. Chem. Commun. 2006: 1064-1066.
55. Port M, Corot C, Raynal I, Idee JM, Dencausse A, Lancelot E, Meyer D, Bonnemain B, Lautrou J. Physicochemical and biological evaluation of P792, a rapid-clearance blood-pool agent for magnetic resonance imaging. Invest. Radiol. 2001; 36: 445-454.
56. Jebasingh B, Alexander V. Synthesis and relaxivity studies of a tetranuclear gadolinium(III) complex of DO3A as a contrast-enhancing agent for MRI. Inorg. Chem. 2005; 44: 9434-9443.
57. Ranganathan RS, Fernandez ME, Kang SI, Nunn AD, Ratsep PC, Pillai KMR, Zhang X, Tweedle MF. New multimeric magnetic resonance imaging agents. Invest. Radiol. 1998; 33: 779-797.
58. Supkowski RM, Horrocks WD Jr. Displacement of inner-sphere water molecules from Eu(3+) analogues of Gd(3+) MRI contrast agents by carbonate and phosphate anions: dissociation constants from luminescence data in the rapid-exchange limit. Inorg. Chem. 1999; 38: 5616-5619.
59. Jocher CJ, Botta M,Avedano S, Moore EG, Xu J, Aime S, Raymond KN. Optimized relaxivity and stability of [Gd(H(2,2)-1,2-HOPO)(H2O)]- for use as an MRI contrast agent. Inorg. Chem. 2007; 46: 4796-4798.
60. Werner EJ, Avedano S, Botta M, Hay BP, Moore EG, Aime S, Raymond KN. Highly soluble tris-hydroxypyridonate Gd(III) complexes with increased hydration number, fast water exchange, slow electronic relaxation, and high relaxivity. J. Am. Chem. Soc. 2007; 129: 1870-1871.
61. Aime S, Botta M, Geninatti Crich S, Giovenzana GB, Jommi G, Pagliarin R, Sisti M. Synthesis and NMR studies of three pyridine containing triaza macrocyclic triacetate ligands and their complexes with lanthanide ions. Inorg. Chem. 1997; 36: 2992-3000.
62. Aime S, Calabi L, Cavallotti C, Gianolio E, Giovenzana GB, Losi P, Maiocchi A, Palmisano G, Sisti M. [Gd-AAZTA]-: a new structural entry for an improved generation of MRI contrast agents. Inorg. Chem. 2004; 43: 7588-7590.
63. Gianolio E, Giovenzana GB, Longo D, Longo I, Menegotto I, Aime S. Relaxometric and modelling studies of the binding of a lipophilic Gd-AAZTA complex to fatted and defatted human serum albumin. Chem. Eur. J. 2007; 13: 5785-5797.
64. Overoye-Chan K, Koerner S, Looby RJ, Kolodziej AF, Zech SG, Deng Q, Chasse JM, McMurry TJ, Caravan P. EP-2104R: a fibrinspecific gadolinium-based MRI contrast agent for detection of thrombus. J. Am. Chem. Soc. 2008; 130: 6025-6039.
65. Schmiedl U, Ogan M, Paajanen H, Marotti M, Crooks LE, Brito AC, Brasch RC. Albumin labeled with Gd-DTPA as an intravascular, blood pool-enhancing agent for MR imaging: biodistribution and imaging studies. Radiology 1987; 162: 205-210.